Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.
Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, El Saghir NS, Arun BK. Al Sukhun S, et al. Among authors: barrios ch. JCO Glob Oncol. 2024 Jan;10:e2300285. doi: 10.1200/GO.23.00285. JCO Glob Oncol. 2024. PMID: 38206277 Free PMC article.
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
Asleh K, Lluch A, Goytain A, Barrios C, Wang XQ, Torrecillas L, Gao D, Ruiz-Borrego M, Leung S, Bines J, Guerrero-Zotano Á, García-Sáenz JÁ, Cejalvo JM, Herranz J, Torres R, Haba-Rodriguez J, Ayala F, Gómez H, Rojo F, Nielsen TO, Martin M. Asleh K, et al. Clin Cancer Res. 2023 Jan 17;29(2):389-400. doi: 10.1158/1078-0432.CCR-22-2191. Clin Cancer Res. 2023. PMID: 36346687 Free PMC article. Clinical Trial.
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
Huober J, Barrios CH, Niikura N, Jarząb M, Chang YC, Huggins-Puhalla SL, Pedrini J, Zhukova L, Graupner V, Eiger D, Henschel V, Gochitashvili N, Lambertini C, Restuccia E, Zhang H; IMpassion050 Trial Investigators. Huober J, et al. Among authors: barrios ch. J Clin Oncol. 2022 Sep 1;40(25):2946-2956. doi: 10.1200/JCO.21.02772. Epub 2022 Jun 28. J Clin Oncol. 2022. PMID: 35763704 Free PMC article. Clinical Trial.
Clinical implication of low estrogen receptor (ER-low) expression in breast cancer.
Reinert T, Cascelli F, de Resende CAA, Gonçalves AC, Godo VSP, Barrios CH. Reinert T, et al. Among authors: barrios ch. Front Endocrinol (Lausanne). 2022 Nov 24;13:1015388. doi: 10.3389/fendo.2022.1015388. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36506043 Free PMC article. Review.
Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420).
Lara Gongora AB, Werutsky G, Jardim DL, Nogueira-Rodrigues A, Barrios CH, Mathias C, Maluf F, Riechelmann R, Fraga M, Gomes H, William WN, Yamada CAF, de Castro G Jr, Rosa DD, de Melo AC, Sala R, Bustamante E, Bretel D, Arrieta O, Cardona AF, Bastos DA. Lara Gongora AB, et al. Among authors: barrios ch. JCO Glob Oncol. 2021 Apr;7:649-658. doi: 10.1200/GO.20.00663. JCO Glob Oncol. 2021. PMID: 33956499 Free PMC article.
168 results